Physician profile
David Bernstein
NPI 1912078304
$405,067.86
in general payments reported to CMS, 2019-2025
29 companies · $179K in 2025
The $179K reported for 2025 was more than what 97% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $7,650 · 2021: $8,277 · 2022: $33K · 2023: $57K · 2024: $78K · 2025: $179K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $178K · Consulting Fee: $59K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $45K · Travel and Lodging: $21K · Food and Beverage: $7,656 · Honoraria: $4,680.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $177,507.31 |
| Consulting Fee | $58,981.45 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $44,950.00 |
| Travel and Lodging | $20,755.11 |
| Food and Beverage | $7,655.74 |
| Honoraria | $4,680.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $93,458.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $87,320.89 | 2019-2024 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $60,362.59 | 2023-2025 | Iqirvo |
| Novo Nordisk INC | $43,384.28 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $31,682.14 | 2024-2025 | |
| Gilead Sciences, INC. | $28,720.61 | 2019-2025 | Livdelzi |
| Abbvie INC. | $12,843.02 | 2019-2024 | |
| Siemens Medical Solutions USA, INC. | $12,522.78 | 2022-2023 | |
| Mirum Pharmaceuticals, INC. | $12,292.44 | 2024-2025 | Livmarli |
| Mallinckrodt Enterprises LLC | $6,396.42 | 2019 | |
| Mallinckrodt Hospital Products INC. | $5,295.74 | 2022-2023 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,709.86 | 2019-2025 | Xifaxan |
| Alnylam Pharmaceuticals INC. | $2,939.72 | 2019 | |
| Pfizer INC. | $1,890.00 | 2021 | |
| Bausch Health US, LLC | $800.00 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $158.77 | 2019 | |
| Horizon Therapeutics Plc | $121.55 | 2019 | |
| Dexcom, INC. | $73.74 | 2024-2025 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $32.11 | 2022 | |
| Lilly USA, LLC | $23.80 | 2025 | Mounjaro |
| Amneal Pharmaceuticals LLC | $22.54 | 2025 | Unithroid |
| Covis Pharma Gmbh | $16.25 | 2019 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.